Company intelligence / Profile preview

Makara

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Makara Therapeutics is a precision immunology company dedicated to developing next-generation therapies for autoimmune and inflammatory diseases. Launched by Third Rock Ventures, the company utilizes a proprietary platform to map immune cell states and identify novel targets for therapeutic intervention. By focusing on specific cell populations and pathways, Makara aims to develop highly targeted therapies that restore immune balance and overcome the limitations of broad-spectrum immunosuppressants. The company is currently in the pre-clinical stage, advancing a pipeline of programs designed to provide more effective and durable clinical outcomes for patients with chronic inflammatory conditions.

Therapeutic areas: Immunology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Makara.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Makara.

Explore the full profile